The original disclosure in Japanese was released on November 9, 2021 at 15:00 (GMT +8)

November 9, 2021
CompanyHeadquarters
Representative
Contact
Telephone
WebsiteTakara Bio Inc. (First Section TSE, code: 4974)
Nojihigashi 7-4-38, Kusatsu, Shiga, Japan
Koichi Nakao, President & CEO
Takuya Kakemi, Executive Officer, Head ofCorporate Management Division(+81)77-565-6970
https://www.takara-bio.co.jp/

Notice of Revisions of Financial Forecast and Dividend Forecast (Dividend Increase)
Takara Bio Inc. (Takara Bio), announced the revisions of the consolidated financial forecast and the dividend
forecast for the fiscal year ending March 31, 2022 (April 1, 2021 – March 31, 2022) that was disclosed on
August 3, 2021, as follows based on a review of current trends in results of operations.

1. Revisions of Financial Forecast(1) Revisions of the consolidated forecast for the fiscal year ending March 2022(April 1, 2021 – March 31, 2022)
Net sales

OperatingprofitOrdinary
profit

Net income
attributable toowners of parent

Net income
per share

Million yen

Million yen

Million yen

Million yen

Yen

Previous forecast (A)54,20017,00017,100

11,90098.82

Revised forecast (B)59,30020,00020,20014,100117.09Amount of change (B-A)

5,100

3,000

3,100

2,200-

Percentage of Change (%)

9.4

17.6

18.1

18.5

-

46,086

13,952

14,159

9,547(Reference) Results for theprevious fiscal year ended
March 31, 2021

79.29

(2) Reason for the Revisions
Sales of Instruments and Gene Therapy are expected to be lower than the previously announced forecast, butthat of Reagents is expected to be higher than the forecast due to sales of new Coronavirus PCR testing-relatedproducts, as well as general research reagents, which are on a recovery trend, and overall sales are expected tobe higher than the forecast. In addition, we expect to increase gross margin due to an improvement in the costof sales ratio in CDMO and other factors. As a result, operating profit, ordinary profit, and net income
attributable to owners of the parent are also expected to exceed the previously announced forecast. Consequently,
the forecast for the full fiscal year has been revised.
For details of the forecasts announced this time, please refer to page 13 of the "Consolidated Financial
Statements for the Second Quarter Ended September 30, 2022 FY2022 (April 1, 2021 – March 31, 2022)[UNAUDITED]" announced today.

The original disclosure in Japanese was released on November 9, 2021 at 15:00 (GMT +8)
2. Revision of Dividend Forecast(1) Details of Revised Dividend Forecast

Record Date
Previous forecast
Revised forecast
Actual results
Results for the previous
fiscal year ended March31, 2021

Cash dividends per share (yen)End of the second half
Year-end
20.00 yen
24.00 yen
0.00 yen
0.00 yen

16.00 yen

Total
20.00 yen
24.00 yen

16.00 yen

(2) Reason for the Revision
Considering the management performance and financial statement comprehensively, Takara Bio recognizes abasic policy aimed for profit contribution, positioning an important business management issue to distributeprofits to shareholders as well as enhancing the internal reserves to strengthen the research development
activities in Bioindustry and Gene Therapy businesses. Specifically, the dividends of surplus will be paid ataround 20% of estimated profit calculated without considering extraordinary income or loss in the consolidated
financial statements.
Based on the above upward revision of the full-year consolidated financial forecast and the above shareholder
return policy, Takara Bio has revised the year-end dividend forecast for the year ending March 2022 from 20.00
to 24.00 per share.
The year-end dividend for the fiscal year ending March 31, 2022 is scheduled to be discussed at the 20th
Ordinary General Meeting of Shareholders to be held in June 2022.

Forward-Looking Statements
Statements contained in these materials with respect to the Company’s current plans, forecasts, strategies and beliefs thatare not historical facts are forward-looking statements about the further performance of the Company and its consolidated
subsidiaries. These statements are based on management’s assumptions and beliefs in light of information currently
available to it, but are based on a number of assumptions and beliefs derived from information that contains significant
risks and uncertainties. Actual results may differ materially from these forecasts due to various factors. Factors that could
influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as
well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors’ prices and productstrategies, declines in selling power of the Company’s existing and new products, disruptions to production, violations of
our intellectual property rights, rapid advances in technology, and unfavorable verdicts in major litigation.